Literature DB >> 19116892

PAMAM dendrimers as potential agents against fibrillation of alpha-synuclein, a Parkinson's disease-related protein.

Agata Rekas1, Victor Lo, Gerry E Gadd, Roberto Cappai, Seok I Yun.   

Abstract

The effect of PAMAM dendrimers (generations G3, G4 and G5) on the fibrillation of alpha-synuclein was examined by fluorescence and CD spectroscopy, TEM and SANS. PAMAM dendrimers inhibited fibrillation of alpha-synuclein and this effect increased both with generation number and PAMAM concentration. SANS showed structural changes in the formed aggregates of alpha-synuclein--from cylindrical to dense three-dimensional ones--as the PAMAM concentration increased, on account of the inhibitory effect. PAMAM also effectively promoted the breaking down of pre-existing fibrils of alpha-synuclein. In both processes--that is, inhibition and disassociation of fibrils--PAMAM redirected alpha-synuclein to an amorphous aggregation pathway.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19116892     DOI： 10.1002/mabi.200800242

Source DB:  PubMed          Journal:  Macromol Biosci        ISSN： 1616-5187            Impact factor:   4.979


  11 in total

Review 1.  Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases.

Authors:  Sibel Bozdağ Pehlivan
Journal:  Pharm Res       Date:  2013-10       Impact factor: 4.200

2.  Nanoparticles for drug delivery in Parkinson's disease.

Authors:  Jonathan Baskin; June Evelyn Jeon; Simon J G Lewis
Journal:  J Neurol       Date:  2020-11-03       Impact factor: 4.849

Review 3.  Nanoparticles in relation to peptide and protein aggregation.

Authors:  Masihuz Zaman; Ejaz Ahmad; Atiyatul Qadeer; Gulam Rabbani; Rizwan Hasan Khan
Journal:  Int J Nanomedicine       Date:  2014-02-12

Review 4.  Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease.

Authors:  Mine Silindir Gunay; A Yekta Ozer; Sylvie Chalon
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

Review 5.  Use of Polyamidoamine Dendrimers in Brain Diseases.

Authors:  Maria Florendo; Alexander Figacz; Bhairavi Srinageshwar; Ajit Sharma; Douglas Swanson; Gary L Dunbar; Julien Rossignol
Journal:  Molecules       Date:  2018-09-03       Impact factor: 4.411

Review 6.  New Advances in General Biomedical Applications of PAMAM Dendrimers.

Authors:  Renan Vinicius de Araújo; Soraya da Silva Santos; Elizabeth Igne Ferreira; Jeanine Giarolla
Journal:  Molecules       Date:  2018-11-02       Impact factor: 4.411

Review 7.  Alpha-Synuclein-Nanoparticle Interactions: Understanding, Controlling and Exploiting Conformational Plasticity.

Authors:  Mariapina D'Onofrio; Francesca Munari; Michael Assfalg
Journal:  Molecules       Date:  2020-11-29       Impact factor: 4.411

8.  In vitro aggregation assays for the characterization of α-synuclein prion-like properties.

Authors:  Joanna Narkiewicz; Gabriele Giachin; Giuseppe Legname
Journal:  Prion       Date:  2014 Jan-Feb       Impact factor: 3.931

9.  Efficient GSH delivery using PAMAM-GSH into MPP-induced PC12 cellular model for Parkinson's disease.

Authors:  Hong-Ji Sun; Yan Wang; Tong Hao; Chang-Yong Wang; Qi-Yu Wang; Xiao-Xia Jiang
Journal:  Regen Biomater       Date:  2016-09-22

Review 10.  The Antiaggregative and Antiamyloidogenic Properties of Nanoparticles: A Promising Tool for the Treatment and Diagnostics of Neurodegenerative Diseases.

Authors:  Monika Pichla; Grzegorz Bartosz; Izabela Sadowska-Bartosz
Journal:  Oxid Med Cell Longev       Date:  2020-10-13       Impact factor: 6.543
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.